Release Summary

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced today positive top-line data from a Phase I study of IW-1973, its lead investigational soluble guanylate cyclase (sGC) stimulator.

Ironwood Pharmaceuticals, Inc.